Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: A nationwide population-based study

Clinical Colorectal Cancer

Volumn 15, Issue 2, 2016, Pages e41-e46

  Razenberg, Lieke G E M ^a,b   Van Gestel, Yvette R B M ^b   Lemmens, Valery E P P ^b,c   De Hingh, Ignace H J T ^a   Creemers, Geert Jan ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b Netherlands Comprehensive Cancer Organization   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Palliative systemic therapy; Peritoneal metastases; Synchronous; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARCINOMATOUS PERITONITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; STANDARD; SYSTEMIC THERAPY; ADENOCARCINOMA; COLORECTAL TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NETHERLANDS; PALLIATIVE CARE; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84952655141     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.12.006     Document Type: Article

References (37)

1. V. Lemmens, L. van Steenbergen, M. Janssen-Heijnen, H. Martijn, H. Rutten, and J.W. Coebergh Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival Acta Oncol 49 2010 784 796
2. V.E. Lemmens, Y.L. Klaver, V.J. Verwaal, H.J. Rutten, J.W. Coebergh, and I.H. de Hingh Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study Int J Cancer 128 2011 2717 2725
3. H.I. Hurwitz, L. Fehrenbacher, J.D. Hainsworth, and et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 2005 3502 3508
4. D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
5. S. Giacchetti, B. Perpoint, R. Zidani, and et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
6. H.J. Meulenbeld, L.N. van Steenbergen, M.L. Janssen-Heijnen, V.E. Lemmens, and G.J. Creemers Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004 Ann Oncol 19 2008 1600 1604
7. F.F. Kabbinavar, J. Schulz, M. McCleod, and et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
8. A. de Gramont, A. Figer, M. Seymour, and et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
9. D.G. Jayne, S. Fook, C. Loi, and F. Seow-Choen Peritoneal carcinomatosis from colorectal cancer Br J Surg 89 2002 1545 1550
10. B. Sadeghi, C. Arvieux, O. Glehen, and et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study Cancer 88 2000 358 363
11. th ed. 2009 Wiley-Blackwell New York
12. rd ed. 2000 World Health Organization Geneva
13. BOM Commissie Raltitrexed, oxaliplatin en irinotecan door commissie BOM beoordeeld Med Oncol 2001 30 33
14. BOM Commissie Bevacizumab bij het colorectaal carcinoom en docetaxel bij het hormoon refractair prostaatcarcinoom Med Oncol 2005 43 49
15. BOM Commissie Herbeoordeling met nieuwe PASKWIL - criteria van de plaats van bevacizumab in de eerstelijns behandeling van het gemetastaseerd colorectaalcarcinoom Med Oncol 2012 31 37
16. R.M. Shaheen, S.A. Ahmad, W. Liu, and et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors Br J Cancer 85 2001 584 589
17. B.K. Zebrowski, W. Liu, K. Ramirez, Y. Akagi, G.B. Mills, and L.M. Ellis Markedly elevated levels of vascular endothelial growth factor in malignant ascites Ann Surg Oncol 6 1999 373 378
18. O. Glehen, F.N. Gilly, F. Boutitie, and et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients Cancer 116 2010 5608 5618
19. A.M. Kuijpers, B. Mirck, A.G. Aalbers, and et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol Ann Surg Oncol 20 2013 4224 4230
20. V.J. Verwaal, S. Bruin, H. Boot, G. van Slooten, and H. van Tinteren 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer Ann Surg Oncol 15 2008 2426 2432
21. V.J. Verwaal, S. Kusamura, D. Baratti, and M. Deraco The eligibility for local-regional treatment of peritoneal surface malignancy J Surg Oncol 98 2008 220 223
22. M.A. Khattak, A.R. Townsend, C. Beeke, and et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer Eur J Cancer 48 2012 1293 1298
23. D. Schrag, L.D. Cramer, P.B. Bach, and C.B. Begg Age and adjuvant chemotherapy use after surgery for stage III colon cancer J Natl Cancer Inst 93 2001 850 857
24. T. McKibbin, C.R. Frei, R.E. Greene, P. Kwan, J. Simon, and J.M. Koeller Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting Oncologist 13 2008 876 885
25. N.J. McCleary, O. Odejide, J. Szymonifka, D. Ryan, A. Hezel, and J.A. Meyerhardt Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer Clin Colorectal Cancer 12 2013 62 69
26. G. Rosati, S. Cordio, R. Bordonaro, and et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study Ann Oncol 21 2010 781 786
27. S. Venderbosch, J. Doornebal, S. Teerenstra, W. Lemmens, C.J. Punt, and M. Koopman Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG) Acta Oncol 51 2012 831 839
28. D. Cunningham, I. Lang, E. Marcuello, and et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial Lancet Oncol 14 2013 1077 1085
29. M.F. Kozloff, J. Berlin, P.J. Flynn, and et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study Oncology 78 2010 329 339
30. J. Feliu, A. Salud, M.J. Safont, and et al. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study Br J Cancer 111 2014 241 248
31. H. Hurwitz, L. Fehrenbacher, W. Novotny, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
32. L.B. Saltz, S. Clarke, E. Diaz-Rubio, and et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
33. A.D. Wagner, D. Arnold, A.A. Grothey, J. Haerting, and S. Unverzagt Anti-angiogenic therapies for metastatic colorectal cancer Cochrane Database Syst Rev 2009 CD005392
34. N.C. Tebbutt, K. Wilson, V.J. Gebski, and et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study J Clin Oncol 28 2010 3191 3198
35. Y.L. Klaver, B.J. Leenders, G.J. Creemers, and et al. Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin Am J Clin Oncol 36 2013 157 161
36. Y.L. Klaver, L.H. Simkens, V.E. Lemmens, and et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy Eur J Surg Oncol 38 2012 617 623
37. T.C. Chua, D.L. Morris, A. Saxena, and et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study Ann Surg Oncol 18 2011 1560 1567